Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACADIA Pharmaceuticals Inc (ACAD) -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (479)	6/16/2008 1:53:41 PM
From: rkrw	Respond to of 588

Interesting acadia fact: when 103 cotherapy with risperdal (I think) came out showing a benefit to the cotherapy, Acadia stock went up $6.92 per share or over 100% on the day to $13.61, on >20M shares. This was March 2007. So acad is now trading for significantly less than it went up that day, despite no bad news in the interim on 103. More a vacuum on it than anything, no promised big pharma JV etc.

To: rkrw who wrote (479)	6/16/2008 3:05:45 PM
From: tuck	Read Replies (1) \| Respond to of 588

Perhaps the Teva hit will stir the partnership interest in pimavanserin up. It'll be interesting to see the actual numbers on the endpoints that Azilect hit. I see the 2mg dose apparently missed one, whereas the 1mg dose hit all of 'em. No mention of dyskinesia outcomes. If those are unaffected, could be room for both drugs? Definitely need to keep an eye on the Azilect data. FWIW, I sold June 5 calls on the spike over $5. It didn't last long and I only got 20 cents. Still, if exercised, that's about 15% in a week, not bad. But so far, I would be comfortable holding for further developments, especially a P partnership. And it looks to me like that will be the scenario, unless some analyst gets some balls and also calls a bottom soon. Cheers, Tuck